Masaharu Ito
President chez Lievence YK
Profil
Masaharu Ito is currently the President & Director at Lievence YK since 2005.
He previously held positions as an Outside Director at UMN Pharma, Inc. in 2012, Director at EA Pharma Co., Ltd., Principal at Pfizer Inc., and Principal at Eisai Co., Ltd.
Dr. Ito received his undergraduate degree from Tohoku University and his doctorate from Asahikawa Medical University.
Postes actifs de Masaharu Ito
| Sociétés | Poste | Début |
|---|---|---|
| Lievence YK | President | 01/01/2005 |
Anciens postes connus de Masaharu Ito
| Sociétés | Poste | Fin |
|---|---|---|
EA Pharma Co., Ltd.
 EA Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., EA Pharma Co., Ltd. is a specialty pharmaceutical company based in Tokyo, Japan. The Japanese company specializes in digestive diseases such as inflammatory intestinal diseases and focuses on advanced research and development and marketing activities to solve unmet medical needs. EA Pharma Co. provides drug discovery research, development research related to gastrointestinal diseases, and drug discovery base technology research to meet the further medical needs of patients. The company's production department aims to create products that have effective and safety as a drug and ensure the quality of the product. EA Pharma Co. aims to be the largest digestive pharmacy in Japan, which was born in the integration of the digestive business of the Eisai group and the Ajinomoto group's digestive business. | Directeur/Membre du Conseil | - |
| EISAI CO., LTD. | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
| UMN PHARMA INC. | Directeur/Membre du Conseil | - |
Formation de Masaharu Ito
| Tohoku University | Undergraduate Degree |
| Asahikawa Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| EISAI CO., LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
EA Pharma Co., Ltd.
EA Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., EA Pharma Co., Ltd. is a specialty pharmaceutical company based in Tokyo, Japan. The Japanese company specializes in digestive diseases such as inflammatory intestinal diseases and focuses on advanced research and development and marketing activities to solve unmet medical needs. EA Pharma Co. provides drug discovery research, development research related to gastrointestinal diseases, and drug discovery base technology research to meet the further medical needs of patients. The company's production department aims to create products that have effective and safety as a drug and ensure the quality of the product. EA Pharma Co. aims to be the largest digestive pharmacy in Japan, which was born in the integration of the digestive business of the Eisai group and the Ajinomoto group's digestive business. | Health Technology |
| Lievence YK |
